Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents.
Fukuokaya W, Kimura T, Onuma H, Mori K, Honda M, Inaba H, Sasaki H, Shimomura T, Miki K, Egawa S. Fukuokaya W, et al. Among authors: honda m. Clin Genitourin Cancer. 2019 Jun;17(3):223-230. doi: 10.1016/j.clgc.2019.04.010. Epub 2019 Apr 16. Clin Genitourin Cancer. 2019. PMID: 31080022
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Fukuokaya W, et al. Among authors: honda m. BJU Int. 2021 Jan;127(1):90-95. doi: 10.1111/bju.15176. Epub 2020 Aug 6. BJU Int. 2021. PMID: 32662189
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Fukuokaya W, et al. Among authors: honda m. Cancer Immunol Immunother. 2022 Jan;71(1):229-236. doi: 10.1007/s00262-021-02980-x. Epub 2021 Jun 8. Cancer Immunol Immunother. 2022. PMID: 34100985 Free PMC article.
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
Kadena S, Urabe F, Iwatani K, Suzuki H, Imai Y, Tashiro K, Tsuzuki S, Honda M, Koike Y, Shimomura T, Aoki M, Sato S, Takahashi H, Miki K, Kimura T. Kadena S, et al. Among authors: honda m. Int J Clin Oncol. 2023 Aug;28(8):1092-1100. doi: 10.1007/s10147-023-02359-1. Epub 2023 May 25. Int J Clin Oncol. 2023. PMID: 37227547
Treatment Results of High-dose-rate Brachytherapy and External Beam Radiation With Long-term Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer.
Suzuki H, Urabe F, Iwatani K, Miyajima K, Imai YU, Tashiro K, Tsuzuki S, Honda M, Koike Y, Aoki M, Sato S, Takahashi H, Miki K, Kimura T. Suzuki H, et al. Among authors: honda m. Anticancer Res. 2023 Jul;43(7):3135-3143. doi: 10.21873/anticanres.16486. Anticancer Res. 2023. PMID: 37352008
Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K, Sato S, Uchida N, Suzuki H, Iwatani K, Imai Y, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Honda M, Koike Y, Miki J, Miki K, Shimomura T, Yuen S, Yamada Y, Aoki M, Takahashi H, Urabe F, Kimura T. Miyajima K, et al. Among authors: honda m. Clin Genitourin Cancer. 2024 Apr;22(2):149-156.e1. doi: 10.1016/j.clgc.2023.10.005. Epub 2023 Oct 25. Clin Genitourin Cancer. 2024. PMID: 38007354
3,011 results